📢 #SjogrensDisease News: Amgen announced that a Phase 3 study evaluating its investigational therapy in patients with moderate-to-severe systemic disease activity met its primary endpoint: amgen.ly/4rsXe7Z$AMGN
SCLC #NEWS: The @FDA approved a label update to the administration information for Amgen’s DLL3-targeting T-cell engager for certain patients with extensive-stage small cell lung cancer (ES-SCLC).
🔗Learn more: amgen.ly/3TuDvIj$AMGN
💡What does progress in small cell lung cancer (SCLC) look like?
At #WCLC26, we’re excited to share our latest research including data from across several studies in small cell lung cancer. Learn more: amgen.ly/4xWu4Ao
On the 25th anniversary of September 11, we remember Dora Menchaca—an Amgen scientist, mentor, mother, wife, and daughter who was aboard Flight 77—along with all the lives lost that day. 🔗amgen.ly/4xLQrZb
📢 #SCLC news: Amgen announced that a Phase 3 study evaluating its DLL3-targeting therapy as part of first-line maintenance treatment for patients with extensive-stage small cell lung cancer met its primary endpoint
➡️ Learn more: amgen.ly/4ihHq5p$AMGN
At Amgen, sustainability is built into how we work. From reducing energy and water use to improving the efficiency of making medicines, environmental sustainability is embedded into our operations.
Learn more: amgen.ly/4zYbitP
Years of waiting. That’s how long it can take to get a Thyroid Eye Disease (TED) diagnosis.
At @ETA_Thyroid’s Annual Meeting, we’re sharing our latest advances in TED and exploring how to help people get answers sooner.
Learn more from the experts.
📢 Amgen presented Phase 3 data at #ESCCongress 2026 highlighting the effect of intensive LDL-C lowering on incidence, type and timing of death among patients at high CV risk for a first heart attack or stroke.
Read more: amgen.ly/4gXQ2gh$AMGN
🔬 Amgen announced positive top-line Phase 3 results in eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus that can impact swallowing and daily life.
🔗 Learn more: amgen.ly/4zy2Ot8$AMGN
For more than a decade, Amgen has led the way in cardiovascular innovation, grounded in science and long-term outcomes evidence.
⬇️ Watch how Amgen is building on that legacy to help redefine LDL (“bad”) cholesterol management for patients today.
Ashok Bhaseen, President of Thyroid Federation International, is attending the @Amgen Advocacy Summit in Thousand Oaks. The event brought together advocacy groups from around the world to share the patient perspective, advocacy goals, and ideas that bring the field forward.
Today's positive opinion from the @EMA_News CHMP is an important step toward expanding treatment options for adults at high cardiovascular risk due to uncontrolled LDL-C, without a prior heart attack or stroke.
Learn more: amgen.ly/4h34Afd$AMGN
#StandUpToCancer has joined forces with @MrBeast and @BeastPhilanthr to create a new SU2C Pediatric Cancer Dream Team focused on finding cures for kids with cancer, fueled by support from @Amgen and @StBaldricks. 🧡✨
1 in 5 children who are diagnosed with cancer will lose their lives to it. YOU can help change that. Donate today to help find cures at StandUpToCancer.org/MrBeastX.
Had the chance to spend time with Jimmy Donaldson (@MrBeast) talking about something that's often invisible: the research behind every breakthrough for children with cancer.
Thank you @SU2C for being such an incredible collaborator on this campaign.
Watch the video: amgen.ly/4x0WYhR#mycompany